This material is the most important excerpt from the clinical guidelines of the European
Cardiological Society (ECS) in 2017 on the use of double antiplatelet therapy (DAT) …

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 antagonist improves
cardiovascular outcomes in patients with acute coronary syndrome but at a cost of an …

Dual antiplatelet therapy (DAPT) is a pillar for the prevention of cardiovascular events
following acute coronary syndromes and/or percutaneous coronary intervention (PCI)(1, 2) …

© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2016; 8 (10): E1226-E1229
jtd. amegroups. com disease. While recognizing the shorter duration of DAPT necessary to …

Background: Dual antiplatelet therapy (DAPT) is one of the cornerstones of coronary artery
disease (CAD) treatment. Standard DAPT requires one of, P2Y12 receptor inhibitors …

Background Dual antiplatelet therapy (DAPT) in the form of aspirin plus a P2Y12 inhibitor,
when indicated, is one of the key treatments in coronary artery disease (CAD). Many …

Background This analysis aimed to evaluate the clinical impact of high bleeding risk (HBR)
on adverse events after percutaneous coronary intervention (PCI). Methods We …

Background Current guidelines recommend extending the use of dual antiplatelet therapy
(DAPT) beyond 1 year in patients with an acute coronary syndrome (ACS) and a high risk of …

Dual antiplatelet therapy (DAPT) with acetylsalicylic acid and a P2Y12 inhibitor is an
established therapy for a broad spectrum of patients with cardiovascular disease. The …

Purpose. The benefits and limitations of current antiplatelet therapies in the management of
patients experiencing acute coronary syndrome (ACS) are reviewed. Summary. Antiplatelet …